HEADER TRANSFERASE 02-MAY-09 2WHA OBSLTE 16-FEB-10 2WHA 2X1N TITLE TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, TITLE 2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN COMPND MOL_ID: 1; COMPND 2 MOLECULE: CYCLIN-DEPENDENT KINASE 2; COMPND 3 CHAIN: A, C; COMPND 4 SYNONYM: P33 PROTEIN KINASE; COMPND 5 EC: 2.7.1.37; COMPND 6 ENGINEERED: YES; COMPND 7 OTHER_DETAILS: TRIAZOL-1-METHYL-PYRIMIDIN INHIBITOR; COMPND 8 MOL_ID: 2; COMPND 9 MOLECULE: CYCLIN A2; COMPND 10 CHAIN: B, D; COMPND 11 FRAGMENT: RESIDUES 172-432; COMPND 12 SYNONYM: CYCLIN-A; COMPND 13 ENGINEERED: YES; COMPND 14 OTHER_DETAILS: TRIPEPTIDE INHIBITOR BOUND TO CYCLIN A COMPND 15 CHAIN D; COMPND 16 MOL_ID: 3; COMPND 17 MOLECULE: LEU-ASN-PFF; COMPND 18 CHAIN: E SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 7108; SOURCE 7 EXPRESSION_SYSTEM_CELL_LINE: SF9; SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: BACULOVIRUS; SOURCE 9 MOL_ID: 2; SOURCE 10 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 11 ORGANISM_COMMON: HUMAN; SOURCE 12 ORGANISM_TAXID: 9606; SOURCE 13 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 14 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 15 MOL_ID: 3; SOURCE 16 SYNTHETIC: YES KEYWDS CDK2, KINASE, CYCLIN, ACTIVE, NUCLEUS, MITOSIS, KEYWDS 2 SERINE/THREONINE-PROTEIN KINASE, CYTOPLASM, INHIBITION, KEYWDS 3 CELL CYCLE, ATP-BINDING, CELL DIVISION, PHOSPHOPROTEIN, KEYWDS 4 NUCLEOTIDE-BINDING, TRANSFERASE, POLYMORPHISM, KEYWDS 5 BETA-PEPTIDE, CYCLIN GROOVE EXPDTA X-RAY DIFFRACTION AUTHOR G.KONTOPIDIS,M.J.ANDREWS,C.MCINNES,A.PLATER,L.INNES, AUTHOR 2 S.RENACHOWSKI,A.COWAN,P.M.FISCHER REVDAT 3 16-FEB-10 2WHA 1 OBSLTE REVDAT 2 16-JUN-09 2WHA 1 REMARK REVDAT 1 09-JUN-09 2WHA 0 JRNL AUTH G.KONTOPIDIS,M.J.ANDREWS,C.MCINNES,A.PLATER, JRNL AUTH 2 L.INNES,S.RENACHOWSKI,A.COWAN,P.M.FISCHER JRNL TITL TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS JRNL TITL 2 OF CYCLIN-DEPENDENT KINASE 2-CYCLIN A THROUGH JRNL TITL 3 STRUCTURE-GUIDED DESIGN. JRNL REF CHEMMEDCHEM 2009 JRNL REFN ESSN 1860-7187 JRNL PMID 19472269 JRNL DOI 10.1002/CMDC.200900093 REMARK 2 REMARK 2 RESOLUTION. 2.75 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.2.0019 REMARK 3 AUTHORS : MURSHUDOV,VAGIN,DODSON REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.75 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 30.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : NONE REMARK 3 COMPLETENESS FOR RANGE (%) : 98.01 REMARK 3 NUMBER OF REFLECTIONS : 33849 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.19737 REMARK 3 R VALUE (WORKING SET) : 0.19545 REMARK 3 FREE R VALUE : 0.25712 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 3.1 REMARK 3 FREE R VALUE TEST SET COUNT : 1097 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.750 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.821 REMARK 3 REFLECTION IN BIN (WORKING SET) : 2486 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 99.07 REMARK 3 BIN R VALUE (WORKING SET) : 0.325 REMARK 3 BIN FREE R VALUE SET COUNT : 76 REMARK 3 BIN FREE R VALUE : 0.372 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 8952 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 32 REMARK 3 SOLVENT ATOMS : 86 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 33.387 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -2.39 REMARK 3 B22 (A**2) : -0.23 REMARK 3 B33 (A**2) : 2.62 REMARK 3 B12 (A**2) : 0.00 REMARK 3 B13 (A**2) : 0.00 REMARK 3 B23 (A**2) : 0.00 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): NULL REMARK 3 ESU BASED ON FREE R VALUE (A): 0.373 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.277 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 13.849 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.937 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.886 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 9266 ; 0.014 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): 6310 ; 0.002 ; 0.020 REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 12592 ; 2.067 ; 1.987 REMARK 3 BOND ANGLES OTHERS (DEGREES): 15427 ; 1.163 ; 3.000 REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 1112 ; 6.070 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 397 ;41.310 ;23.904 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 1628 ;18.174 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 46 ;20.151 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 1418 ; 0.115 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 10056 ; 0.010 ; 0.020 REMARK 3 GENERAL PLANES OTHERS (A): 1820 ; 0.004 ; 0.020 REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): 1983 ; 0.242 ; 0.300 REMARK 3 NON-BONDED CONTACTS OTHERS (A): 6199 ; 0.225 ; 0.300 REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): 4516 ; 0.200 ; 0.500 REMARK 3 NON-BONDED TORSION OTHERS (A): 4717 ; 0.103 ; 0.500 REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): 324 ; 0.196 ; 0.500 REMARK 3 H-BOND (X...Y) OTHERS (A): 2 ; 0.054 ; 0.500 REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): 14 ; 0.191 ; 0.300 REMARK 3 SYMMETRY VDW OTHERS (A): 30 ; 0.396 ; 0.300 REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): 5 ; 0.319 ; 0.500 REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 5703 ; 1.899 ; 1.500 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): 2201 ; 0.481 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 9058 ; 3.123 ; 2.000 REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 3994 ; 4.722 ; 3.000 REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 3530 ; 7.100 ; 4.500 REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : 2 REMARK 3 REMARK 3 NCS GROUP NUMBER : 1 REMARK 3 CHAIN NAMES : A C REMARK 3 NUMBER OF COMPONENTS NCS GROUP : 1 REMARK 3 COMPONENT C SSSEQI TO C SSSEQI CODE REMARK 3 1 A 1 A 298 3 REMARK 3 1 C 1 C 298 3 REMARK 3 GROUP CHAIN COUNT RMS WEIGHT REMARK 3 TIGHT POSITIONAL 1 A (A): 1734 ; 0.19 ; 0.05 REMARK 3 LOOSE POSITIONAL 1 A (A): 2285 ; 0.59 ; 5.00 REMARK 3 TIGHT THERMAL 1 A (A**2): 1734 ; 0.38 ; 0.50 REMARK 3 LOOSE THERMAL 1 A (A**2): 2285 ; 2.43 ; 10.00 REMARK 3 TIGHT POSITIONAL 1 C (A): 1734 ; 0.19 ; 0.05 REMARK 3 LOOSE POSITIONAL 1 C (A): 2285 ; 0.59 ; 5.00 REMARK 3 TIGHT THERMAL 1 C (A**2): 1734 ; 0.38 ; 0.50 REMARK 3 LOOSE THERMAL 1 C (A**2): 2285 ; 2.43 ; 10.00 REMARK 3 REMARK 3 NCS GROUP NUMBER : 2 REMARK 3 CHAIN NAMES : B D REMARK 3 NUMBER OF COMPONENTS NCS GROUP : 1 REMARK 3 COMPONENT C SSSEQI TO C SSSEQI CODE REMARK 3 1 B 175 B 432 3 REMARK 3 1 D 175 D 432 3 REMARK 3 GROUP CHAIN COUNT RMS WEIGHT REMARK 3 TIGHT POSITIONAL 2 B (A): 1521 ; 0.16 ; 0.05 REMARK 3 LOOSE POSITIONAL 2 B (A): 1973 ; 0.54 ; 5.00 REMARK 3 TIGHT THERMAL 2 B (A**2): 1521 ; 0.34 ; 0.50 REMARK 3 LOOSE THERMAL 2 B (A**2): 1973 ; 2.41 ; 10.00 REMARK 3 TIGHT POSITIONAL 2 D (A): 1521 ; 0.16 ; 0.05 REMARK 3 LOOSE POSITIONAL 2 D (A): 1973 ; 0.54 ; 5.00 REMARK 3 TIGHT THERMAL 2 D (A**2): 1521 ; 0.34 ; 0.50 REMARK 3 LOOSE THERMAL 2 D (A**2): 1973 ; 2.41 ; 10.00 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.20 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE REMARK 3 RIDING POSITIONS. REMARK 4 REMARK 4 2WHA COMPLIES WITH FORMAT V. 3.20, 01-DEC-08 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 05-MAY-09. REMARK 100 THE PDBE ID CODE IS EBI-39681. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 12-FEB-03 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 7.8 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID14-2 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.933 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : MIRRORS REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 37669 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.75 REMARK 200 RESOLUTION RANGE LOW (A) : 30.00 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 3.0 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 98.3 REMARK 200 DATA REDUNDANCY : 3.8 REMARK 200 R MERGE (I) : 0.14 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 12.70 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.75 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.90 REMARK 200 COMPLETENESS FOR SHELL (%) : 98.8 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 0.67 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 1.90 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: MOLREP REMARK 200 STARTING MODEL: PDB ENTRY 1OL1 REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 50.02 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.48 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: PEG3350 20% V/V, 0.1M REMARK 280 TRI-SODIUM CITRATE REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 37.27900 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 78.63850 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 57.12850 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 78.63850 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 37.27900 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 57.12850 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 GENERATING THE BIOMOLECULE REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 3390 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 23970 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -15.4 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TRIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: TRIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 4090 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 23960 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -17.6 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: C, D, E REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 ARG A 297 REMARK 465 LEU A 298 REMARK 465 VAL B 172 REMARK 465 ASN B 173 REMARK 465 GLU B 174 REMARK 465 LEU C 298 REMARK 465 VAL D 172 REMARK 465 ASN D 173 REMARK 465 GLU D 174 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 LEU B 432 O REMARK 470 ARG C 297 NH1 NH2 REMARK 470 ARG C 297 CA C O CB CG CD NE CZ REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 NZ LYS A 6 - NZ LYS A 34 1.96 REMARK 500 OE1 GLU A 162 - OH TYR A 180 1.87 REMARK 500 O VAL B 279 - OG1 THR B 282 2.17 REMARK 500 O THR B 282 - CG2 THR B 285 2.03 REMARK 500 OH TYR C 15 - OE1 GLU C 51 2.02 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND LENGTHS REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,2(A3,1X,A1,I4,A1,1X,A4,3X),1X,F6.3) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 RES CSSEQI ATM2 DEVIATION REMARK 500 CYS C 177 CB CYS C 177 SG -0.115 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 LEU A 32 CB - CG - CD1 ANGL. DEV. = -10.5 DEGREES REMARK 500 GLU A 40 N - CA - C ANGL. DEV. = -19.4 DEGREES REMARK 500 ASP A 92 CB - CG - OD1 ANGL. DEV. = 7.9 DEGREES REMARK 500 ASP A 92 CB - CG - OD2 ANGL. DEV. = -5.5 DEGREES REMARK 500 MET C 1 CG - SD - CE ANGL. DEV. = 10.6 DEGREES REMARK 500 ILE C 35 CB - CA - C ANGL. DEV. = -12.6 DEGREES REMARK 500 VAL C 64 CB - CA - C ANGL. DEV. = -13.2 DEGREES REMARK 500 LEU C 124 CB - CG - CD2 ANGL. DEV. = -12.0 DEGREES REMARK 500 CYS C 177 CA - CB - SG ANGL. DEV. = -15.0 DEGREES REMARK 500 ASP C 185 CB - CG - OD1 ANGL. DEV. = 5.8 DEGREES REMARK 500 ARG D 293 NE - CZ - NH1 ANGL. DEV. = -3.0 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 TYR A 15 26.79 111.64 REMARK 500 ARG A 36 120.98 27.38 REMARK 500 GLU A 40 145.98 164.62 REMARK 500 THR A 41 -140.98 94.81 REMARK 500 LEU A 96 -60.78 73.15 REMARK 500 ARG A 126 -11.59 80.60 REMARK 500 ASP A 127 49.49 -141.35 REMARK 500 ASP A 145 79.18 56.81 REMARK 500 PHE A 152 42.88 -107.28 REMARK 500 THR A 165 160.91 110.30 REMARK 500 TRP A 227 83.66 -150.93 REMARK 500 ASP A 256 -168.27 -71.65 REMARK 500 PRO B 176 3.25 -35.04 REMARK 500 ASP B 283 46.01 73.35 REMARK 500 PHE B 304 26.06 46.11 REMARK 500 ASN B 431 42.59 71.03 REMARK 500 THR C 14 31.91 -98.45 REMARK 500 TYR C 15 -30.78 -171.74 REMARK 500 ASP C 38 -170.04 -39.13 REMARK 500 GLU C 40 -7.13 109.41 REMARK 500 THR C 41 -168.08 -53.28 REMARK 500 LEU C 96 -54.75 72.13 REMARK 500 ARG C 126 -12.96 71.40 REMARK 500 ASP C 145 78.99 55.26 REMARK 500 THR C 160 -57.57 87.33 REMARK 500 GLU C 162 -110.92 30.63 REMARK 500 VAL C 163 -1.94 81.07 REMARK 500 LEU C 166 -165.18 89.04 REMARK 500 TRP C 167 -65.65 50.56 REMARK 500 ARG C 199 16.69 59.18 REMARK 500 TRP C 227 80.45 -159.30 REMARK 500 PRO C 254 4.46 -63.57 REMARK 500 PRO D 176 164.05 -39.50 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: MAIN CHAIN PLANARITY REMARK 500 REMARK 500 THE FOLLOWING RESIDUES HAVE A PSEUDO PLANARITY REMARK 500 TORSION, C(I) - CA(I) - N(I+1) - O(I), GREATER REMARK 500 10.0 DEGREES. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 500 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 500 I=INSERTION CODE). REMARK 500 REMARK 500 M RES CSSEQI ANGLE REMARK 500 ASP D 345 10.71 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CHIRAL CENTERS REMARK 500 REMARK 500 UNEXPECTED CONFIGURATION OF THE FOLLOWING CHIRAL REMARK 500 CENTER(S) USING IMPROPER CA--C--CB--N CHIRALITY REMARK 500 M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,6X,F5.1,6X,A1,10X,A1,3X,A16) REMARK 500 REMARK 500 M RES CSSEQI IMPROPER EXPECTED FOUND DETAILS REMARK 500 TYR A 15 22.6 L L OUTSIDE RANGE REMARK 500 THR A 39 23.2 L L OUTSIDE RANGE REMARK 500 REMARK 500 REMARK: NULL REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 600 REMARK 600 HETEROGEN REMARK 600 CHAIN E COULD BE REPRESENTED AS A SINGLE HETEROGEN REMARK 600 WITH NAME: REMARK 600 (S)-2-((S)-2-ACETAMIDO-4-METHYLPENTANAMIDO)-N1-((S)-1-AMINO-3- REMARK 600 (4-FLUORIDE) REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1H08 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 REMARK 900 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR REMARK 900 RELATED ID: 1PYE RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR REMARK 900 RELATED ID: 2VTH RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 REMARK 900 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- REMARK 900 CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- REMARK 900 RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG REMARK 900 DESIGN. REMARK 900 RELATED ID: 1V1K RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 REMARK 900 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR REMARK 900 RELATED ID: 2B53 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) REMARK 900 COMPLEXED WITH DIN-234325 REMARK 900 RELATED ID: 1H25 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE REMARK 900 RECRUITMENT PEPTIDE FROM E2F REMARK 900 RELATED ID: 1OKV RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- REMARK 900 ARG-LEU-ILE-PHE-NH2 REMARK 900 RELATED ID: 1KE7 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED REMARK 900 WITH 3-{[(2,2-DIOXIDO-1,3-DIHYDRO-2- REMARK 900 BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3- REMARK 900 OXAZOL-5-YL)-1,3-DIHYDRO-2H-INDOL-2- REMARK 900 ONE REMARK 900 RELATED ID: 1PXK RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED REMARK 900 WITH THEINHIBITOR N-[4-(2,4-DIMETHYL- REMARK 900 THIAZOL-5-YL)PYRIMIDIN-2-YL]-N'- REMARK 900 HYDROXYIMINOFORMAMIDE REMARK 900 RELATED ID: 2BHH RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN REMARK 900 COMPLEX WITH THE INHIBITOR 4- REMARK 900 HYDROXYPIPERINDINESULFONYL-INDIRUBINE REMARK 900 RELATED ID: 2VTA RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 REMARK 900 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- REMARK 900 CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- REMARK 900 RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG REMARK 900 DESIGN. REMARK 900 RELATED ID: 2UUE RELATED DB: PDB REMARK 900 REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF REMARK 900 CYCLIN BINDING GROOVE INHIBITORS REMARK 900 RELATED ID: 1GZ8 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED REMARK 900 WITH THE INHIBITOR 2-AMINO-6-(3'-METHYL- REMARK 900 2'-OXO)BUTOXYPURINE REMARK 900 RELATED ID: 1E1V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED REMARK 900 WITH THE INHIBITOR NU2058 REMARK 900 RELATED ID: 1OL2 RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- REMARK 900 ARG-LEU-ASN-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1H27 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE REMARK 900 RECRUITMENT PEPTIDE FROM P27 REMARK 900 RELATED ID: 1JSV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 REMARK 900 (CDK2) INCOMPLEX WITH 4-[(6-AMINO-4- REMARK 900 PYRIMIDINYL)AMINO]BENZENESULFONAMIDE REMARK 900 RELATED ID: 2B52 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) REMARK 900 COMPLEXED WITH DPH-042562 REMARK 900 RELATED ID: 1KE5 RELATED DB: PDB REMARK 900 CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO- REMARK 900 1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL] REMARK 900 AMINO}BENZENESULFONAMIDE REMARK 900 RELATED ID: 1FIN RELATED DB: PDB REMARK 900 CYCLIN A - CYCLIN-DEPENDENT KINASE 2 COMPLEX REMARK 900 RELATED ID: 2C5O RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE REMARK 900 AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG REMARK 900 DESIGN REMARK 900 RELATED ID: 2C68 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 REMARK 900 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1P2A RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 REMARK 900 (CKD2) WITH ATRISUBSTITUTED NAPHTHOSTYRIL REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2VTT RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 REMARK 900 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- REMARK 900 CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- REMARK 900 RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG REMARK 900 DESIGN. REMARK 900 RELATED ID: 2C4G RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514 REMARK 900 RELATED ID: 2VTQ RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 REMARK 900 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- REMARK 900 CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- REMARK 900 RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG REMARK 900 DESIGN. REMARK 900 RELATED ID: 1W0X RELATED DB: PDB REMARK 900 CRYSTALS STRUCTURE OF HUMAN CDK2 IN COMPLEX REMARK 900 WITH THE INHIBITOR OLOMOUCINE. REMARK 900 RELATED ID: 1H1Q RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ REMARK 900 CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094 REMARK 900 RELATED ID: 2W05 RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 IN COMPLEX WITH AN REMARK 900 IMIDAZOLYL PYRIMIDINE, COMPOUND 5B REMARK 900 RELATED ID: 1PXO RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED REMARK 900 WITH THEINHIBITOR [4-(2-AMINO-4-METHYL- REMARK 900 THIAZOL-5-YL)-PYRIMIDIN-2-YL]-(3-NITRO- REMARK 900 PHENYL)-AMINE REMARK 900 RELATED ID: 1KE9 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED REMARK 900 WITH 3-{[4-({[AMINO(IMINO)METHYL] REMARK 900 AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3- REMARK 900 DIHYDRO-1H-INDOLE REMARK 900 RELATED ID: 1HCK RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 2A0C RELATED DB: PDB REMARK 900 HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II, REMARK 900 A NOVEL 2,6,9-TRISUBSTITUTED PURINE CYCLIN REMARK 900 -DEPENDENT KINASE INHIBITOR REMARK 900 RELATED ID: 1JSU RELATED DB: PDB REMARK 900 P27(KIP1)/CYCLIN A/CDK2 COMPLEX REMARK 900 RELATED ID: 1PXN RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED REMARK 900 WITH THEINHIBITOR 4-[4-(4-METHYL-2- REMARK 900 METHYLAMINO-THIAZOL-5-YL)-PYRIMIDIN-2- REMARK 900 YLAMINO]-PHENOL REMARK 900 RELATED ID: 2UZE RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED REMARK 900 WITH A THIAZOLIDINONE INHIBITOR REMARK 900 RELATED ID: 2V0D RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED REMARK 900 WITH A THIAZOLIDINONE INHIBITOR REMARK 900 RELATED ID: 2VTM RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 REMARK 900 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- REMARK 900 CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- REMARK 900 RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG REMARK 900 DESIGN. REMARK 900 RELATED ID: 1OIQ RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS REMARK 900 OF CYCLIN-DEPENDENT KINASE INHIBITORS REMARK 900 IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1H1R RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ REMARK 900 CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086 REMARK 900 RELATED ID: 2IW8 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2- REMARK 900 CYCLIN A F82H-L83V-H84D MUTANT WITH AN REMARK 900 O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR REMARK 900 RELATED ID: 1PW2 RELATED DB: PDB REMARK 900 APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT REMARK 900 KINASE 2 REMARK 900 RELATED ID: 1HCL RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1GIH RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED REMARK 900 WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 2VTN RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 REMARK 900 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- REMARK 900 CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- REMARK 900 RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG REMARK 900 DESIGN. REMARK 900 RELATED ID: 2W06 RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 IN COMPLEX WITH AN REMARK 900 IMIDAZOLYL PYRIMIDINE, COMPOUND 5C REMARK 900 RELATED ID: 1JST RELATED DB: PDB REMARK 900 PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND REMARK 900 TO CYCLIN A REMARK 900 RELATED ID: 1OIU RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ REMARK 900 CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 1PXM RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED REMARK 900 WITH THEINHIBITOR 3-[4-(2,4-DIMETHYL- REMARK 900 THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINO]-PHENOL REMARK 900 RELATED ID: 1B38 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1FQ1 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF KINASE ASSOCIATED REMARK 900 PHOSPHATASE (KAP) INCOMPLEX WITH PHOSPHO-CDK2 REMARK 900 RELATED ID: 1VYW RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137 REMARK 900 RELATED ID: 1H1P RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ REMARK 900 CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058 REMARK 900 RELATED ID: 2C69 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 REMARK 900 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1URC RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- REMARK 900 ARG-LEU-ASN-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1PXI RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED REMARK 900 WITH THEINHIBITOR 4-(2,5-DICHLORO-THIOPHEN- REMARK 900 3-YL)-PYRIMIDIN-2-YLAMINE REMARK 900 RELATED ID: 2C6I RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 REMARK 900 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1YKR RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CDK2 WITH AN REMARK 900 AMINOIMIDAZO PYRIDINEINHIBITOR REMARK 900 RELATED ID: 2W17 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH THE IMIDAZOLE REMARK 900 PYRIMIDINE AMIDE, COMPOUND (S)-8B REMARK 900 RELATED ID: 2C6K RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 REMARK 900 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C5Y RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE REMARK 900 AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG REMARK 900 DESIGN REMARK 900 RELATED ID: 2UZD RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED REMARK 900 WITH A THIAZOLIDINONE INHIBITOR REMARK 900 RELATED ID: 1WCC RELATED DB: PDB REMARK 900 SCREENING FOR FRAGMENT BINDING BY X-RAY REMARK 900 CRYSTALLOGRAPHY REMARK 900 RELATED ID: 2J9M RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH REMARK 900 MACROCYCLIC AMINOPYRIMIDINE REMARK 900 RELATED ID: 1VYZ RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227 REMARK 900 RELATED ID: 2VTI RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 REMARK 900 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- REMARK 900 CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- REMARK 900 RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG REMARK 900 DESIGN. REMARK 900 RELATED ID: 1JVP RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 ( REMARK 900 UNPHOSPHORYLATED) INCOMPLEX WITH PKF049-365 REMARK 900 RELATED ID: 1W98 RELATED DB: PDB REMARK 900 THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY REMARK 900 CYCLIN E REMARK 900 RELATED ID: 1PKD RELATED DB: PDB REMARK 900 THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX REMARK 900 WITH PHOSPHO-CDK2/CYCLIN A REMARK 900 RELATED ID: 1P5E RELATED DB: PDB REMARK 900 THE STRUCURE OF PHOSPHO-CDK2/CYCLIN A IN REMARK 900 COMPLEX WITH THEINHIBITOR 4,5,6,7- REMARK 900 TETRABROMOBENZOTRIAZOLE (TBS) REMARK 900 RELATED ID: 2VTS RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 REMARK 900 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- REMARK 900 CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- REMARK 900 RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG REMARK 900 DESIGN. REMARK 900 RELATED ID: 2C5P RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE REMARK 900 AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG REMARK 900 DESIGN REMARK 900 RELATED ID: 2UZN RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED REMARK 900 WITH A THIAZOLIDINONE INHIBITOR REMARK 900 RELATED ID: 2B54 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2) REMARK 900 COMPLEXED WITH DIN-232305 REMARK 900 RELATED ID: 1KE6 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED REMARK 900 WITH N-METHYL-{4-[2-(7-OXO-6,7-DIHYDRO REMARK 900 -8H-[1,3]THIAZOLO[5,4-E]INDOL-8- REMARK 900 YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE REMARK 900 RELATED ID: 1PXJ RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED REMARK 900 WITH THEINHIBITOR 4-(2,4-DIMETHYL-THIAZOL- REMARK 900 5-YL)-PYRIMIDIN-2-YLAMINE REMARK 900 RELATED ID: 2UZL RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED REMARK 900 WITH A THIAZOLIDINONE INHIBITOR REMARK 900 RELATED ID: 2CCI RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A REMARK 900 IN COMPLEX WITH A PEPTIDE CONTAINING BOTH REMARK 900 THE SUBSTRATE AND RECRUITMENT SITES OF CDC6 REMARK 900 RELATED ID: 2G9X RELATED DB: PDB REMARK 900 STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/ REMARK 900 CYCLIN A INCOMPLEX WITH THE INHIBITOR NU6271 REMARK 900 RELATED ID: 2BKZ RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611 REMARK 900 RELATED ID: 1Y91 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED REMARK 900 WITH A PYRAZOLO[1,5-A]PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2IW6 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2- REMARK 900 CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1GIJ RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED REMARK 900 WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1R78 RELATED DB: PDB REMARK 900 CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1H0V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN REMARK 900 COMPLEX WITH THE INHIBITOR 2-AMINO-6-[(R REMARK 900 )-PYRROLIDINO-5'-YL]METHOXYPURINE REMARK 900 RELATED ID: 2IW9 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2- REMARK 900 CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1W8C RELATED DB: PDB REMARK 900 CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY- REMARK 900 8-ISOPROPYL-9H-PURIN-2-YLAMINE AND REMARK 900 MONOMERIC CDK2 REMARK 900 RELATED ID: 1BUH RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE REMARK 900 COMPLEX WITHCELL CYCLE-REGULATORY PROTEIN REMARK 900 CKSHS1 REMARK 900 RELATED ID: 2BPM RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529 REMARK 900 RELATED ID: 2BTS RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032 REMARK 900 RELATED ID: 1FVV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX REMARK 900 WITH AN OXINDOLEINHIBITOR REMARK 900 RELATED ID: 1OKW RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR AC-ARG- REMARK 900 ARG-LEU-ASN-(M-CL-PHE)-NH2 REMARK 900 RELATED ID: 2VTP RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 REMARK 900 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- REMARK 900 CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- REMARK 900 RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG REMARK 900 DESIGN. REMARK 900 RELATED ID: 2A4L RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 IN COMPLEX REMARK 900 WITH ROSCOVITINE REMARK 900 RELATED ID: 2C6T RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 REMARK 900 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1FVT RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 REMARK 900 (CDK2) INCOMPLEX WITH AN OXINDOLE INHIBITOR REMARK 900 RELATED ID: 1QMZ RELATED DB: PDB REMARK 900 PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE REMARK 900 PEPTIDE COMPLEX REMARK 900 RELATED ID: 2W1H RELATED DB: PDB REMARK 900 FRAGMENT-BASED DISCOVERY OF THE PYRAZOL-4- REMARK 900 YL UREA (AT9283), A MULTI-TARGETED KINASE REMARK 900 INHIBITOR WITH POTENT AURORA KINASE ACTIVITY REMARK 900 RELATED ID: 2VU3 RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 REMARK 900 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- REMARK 900 CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- REMARK 900 RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG REMARK 900 DESIGN. REMARK 900 RELATED ID: 1OGU RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ REMARK 900 CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4- REMARK 900 CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2B55 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) REMARK 900 COMPLEXED WITHINDENOPYRAXOLE DIN-101312 REMARK 900 RELATED ID: 1PF8 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT REMARK 900 KINASE 2COMPLEXED WITH A NUCLEOSIDE INHIBITOR REMARK 900 RELATED ID: 1H1S RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ REMARK 900 CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102 REMARK 900 RELATED ID: 2C5V RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE REMARK 900 AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG REMARK 900 DESIGN REMARK 900 RELATED ID: 2JGZ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX REMARK 900 WITH CYCLIN B REMARK 900 RELATED ID: 2BHE RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN REMARK 900 COMPLEX WITH THE INHIBITOR 5-BROMO- REMARK 900 INDIRUBINE REMARK 900 RELATED ID: 1URW RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH AN IMIDAZO[1,2-B] REMARK 900 PYRIDAZINE REMARK 900 RELATED ID: 1OIY RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ REMARK 900 CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 2C6L RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 REMARK 900 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1F5Q RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS REMARK 900 CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDANT REMARK 900 KINASE 2 REMARK 900 RELATED ID: 2C6O RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 REMARK 900 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2VTL RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 REMARK 900 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- REMARK 900 CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- REMARK 900 RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG REMARK 900 DESIGN. REMARK 900 RELATED ID: 1OL1 RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-CIT- REMARK 900 CIT-LEU-ILE-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 2UZB RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED REMARK 900 WITH A THIAZOLIDINONE INHIBITOR REMARK 900 RELATED ID: 1H01 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 REMARK 900 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR REMARK 900 RELATED ID: 2WFY RELATED DB: PDB REMARK 900 TRUNCATION AND OPTIMISATION OF PEPTIDE REMARK 900 INHIBITORS OF CDK2, CYCLIN A THROUGH REMARK 900 STRUCTURE GUIDED DESIGN REMARK 900 RELATED ID: 1OIR RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS REMARK 900 OF CYCLIN-DEPENDENT KINASE INHIBITORS REMARK 900 IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1OI9 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ REMARK 900 CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 2VTJ RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 REMARK 900 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- REMARK 900 CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- REMARK 900 RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG REMARK 900 DESIGN. REMARK 900 RELATED ID: 2CJM RELATED DB: PDB REMARK 900 MECHANISM OF CDK INHIBITION BY ACTIVE SITE REMARK 900 PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX REMARK 900 WITH CYCLIN A STRUCTURE REMARK 900 RELATED ID: 2C5N RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE REMARK 900 AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG REMARK 900 DESIGN REMARK 900 RELATED ID: 2C5X RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE REMARK 900 AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG REMARK 900 DESIGN REMARK 900 RELATED ID: 2WEV RELATED DB: PDB REMARK 900 TRUNCATION AND OPTIMISATION OF PEPTIDE REMARK 900 INHIBITORS OF CDK2, CYCLIN A THROUGH REMARK 900 STRUCTURE GUIDED DESIGN REMARK 900 RELATED ID: 2C6M RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 REMARK 900 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1OIT RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS REMARK 900 OF CYCLIN-DEPENDENT KINASE INHIBITORS REMARK 900 IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1GY3 RELATED DB: PDB REMARK 900 PCDK2/CYCLIN A IN COMPLEX WITH MGADP, REMARK 900 NITRATE AND PEPTIDE SUBSTRATE REMARK 900 RELATED ID: 2V22 RELATED DB: PDB REMARK 900 REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF REMARK 900 CYCLIN BINDING GROOVE INHIBITORS REMARK 900 RELATED ID: 1GII RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED REMARK 900 WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1DI8 RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 REMARK 900 (CDK2) IN COMPLEX WITH 4-[3- REMARK 900 HYDROXYANILINO]-6,7-DIMETHOXYQUINAZOLINE REMARK 900 RELATED ID: 2VV9 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH AN IMIDAZOLE PIPERAZINE REMARK 900 RELATED ID: 1E9H RELATED DB: PDB REMARK 900 THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN REMARK 900 A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5- REMARK 900 SULPHONATE BOUND REMARK 900 RELATED ID: 1DM2 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED REMARK 900 WITH THE INHIBITOR HYMENIALDISINE REMARK 900 RELATED ID: 2VTO RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 REMARK 900 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- REMARK 900 CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- REMARK 900 RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG REMARK 900 DESIGN. REMARK 900 RELATED ID: 2UZO RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED REMARK 900 WITH A THIAZOLIDINONE INHIBITOR REMARK 900 RELATED ID: 1H24 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH A 9 RESIDUE REMARK 900 RECRUITMENT PEPTIDE FROM E2F REMARK 900 RELATED ID: 2EXM RELATED DB: PDB REMARK 900 HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE REMARK 900 RELATED ID: 1H00 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 REMARK 900 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR REMARK 900 RELATED ID: 2CLX RELATED DB: PDB REMARK 900 4-ARYLAZO-3,5-DIAMINO-1H-PYRAZOLE CDK REMARK 900 INHIBITORS: SAR STUDY, CRYSTAL STRUCTURE IN REMARK 900 COMPLEX WITH CDK2, SELECTIVITY, AND CELLULAR REMARK 900 EFFECTS REMARK 900 RELATED ID: 1PXP RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED REMARK 900 WITH THEINHIBITOR N-[4-(2,4-DIMETHYL- REMARK 900 THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'- REMARK 900 DIMETHYL-BENZENE-1,4-DIAMINE REMARK 900 RELATED ID: 2CCH RELATED DB: PDB REMARK 900 THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN REMARK 900 COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED REMARK 900 FROM CDC MODIFIED WITH A GAMMA-LINKED ATP REMARK 900 ANALOGUE REMARK 900 RELATED ID: 2BTR RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873 REMARK 900 RELATED ID: 1B39 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED REMARK 900 ON THR 160 REMARK 900 RELATED ID: 1AQ1 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED REMARK 900 WITH THE INHIBITOR STAUROSPORINE REMARK 900 RELATED ID: 1H0W RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN REMARK 900 COMPLEX WITH THE INHIBITOR 2-AMINO-6-[ REMARK 900 CYCLOHEX-3-ENYL]METHOXYPURINE REMARK 900 RELATED ID: 1CKP RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED REMARK 900 WITH THE INHIBITOR PURVALANOL B REMARK 900 RELATED ID: 1G5S RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT REMARK 900 KINASE 2 (CDK2)IN COMPLEX WITH THE REMARK 900 INHIBITOR H717 REMARK 900 RELATED ID: 1KE8 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED REMARK 900 WITH 4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3 REMARK 900 -YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2- REMARK 900 YL)BENZENESULFONAMIDE REMARK 900 RELATED ID: 1PXL RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED REMARK 900 WITH THEINHIBITOR [4-(2,4-DIMETHYL-THIAZOL- REMARK 900 5-YL)-PYRIMIDIN-2-YL]-(4-TRIFLUOROMETHYL- REMARK 900 PHENYL)-AMINE REMARK 900 RELATED ID: 1H28 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE REMARK 900 RECRUITMENT PEPTIDE FROM P107 REMARK 900 RELATED ID: 1H26 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE REMARK 900 RECRUITMENT PEPTIDE FROM P53 REMARK 900 RELATED ID: 2VTR RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 REMARK 900 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- REMARK 900 CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- REMARK 900 RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG REMARK 900 DESIGN. REMARK 900 RELATED ID: 1H07 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 REMARK 900 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR REMARK 900 RELATED ID: 1E1X RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED REMARK 900 WITH THE INHIBITOR NU6027 REMARK 900 RELATED ID: 1Y8Y RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED REMARK 900 WITH A PYRAZOLO[1,5-A]PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2WHB RELATED DB: PDB REMARK 900 TRUNCATION AND OPTIMISATION OF PEPTIDE REMARK 900 INHIBITORS OF CDK2, CYCLIN A THROUGH REMARK 900 STRUCTURE GUIDED DESIGN REMARK 999 REMARK 999 SEQUENCE REMARK 999 FRACTION 172-432 CRYSTALLISED IN COMPLEX WITH CDK2 DBREF 2WHA A 1 298 UNP P24941 CDK2_HUMAN 1 298 DBREF 2WHA B 172 432 UNP P20248 CCNA2_HUMAN 172 432 DBREF 2WHA C 1 298 UNP P24941 CDK2_HUMAN 1 298 DBREF 2WHA D 172 432 UNP P20248 CCNA2_HUMAN 172 432 DBREF 2WHA E 1 5 PDB 2WHA 2WHA 1 5 SEQRES 1 A 298 MET GLU ASN PHE GLN LYS VAL GLU LYS ILE GLY GLU GLY SEQRES 2 A 298 THR TYR GLY VAL VAL TYR LYS ALA ARG ASN LYS LEU THR SEQRES 3 A 298 GLY GLU VAL VAL ALA LEU LYS LYS ILE ARG LEU ASP THR SEQRES 4 A 298 GLU THR GLU GLY VAL PRO SER THR ALA ILE ARG GLU ILE SEQRES 5 A 298 SER LEU LEU LYS GLU LEU ASN HIS PRO ASN ILE VAL LYS SEQRES 6 A 298 LEU LEU ASP VAL ILE HIS THR GLU ASN LYS LEU TYR LEU SEQRES 7 A 298 VAL PHE GLU PHE LEU HIS GLN ASP LEU LYS LYS PHE MET SEQRES 8 A 298 ASP ALA SER ALA LEU THR GLY ILE PRO LEU PRO LEU ILE SEQRES 9 A 298 LYS SER TYR LEU PHE GLN LEU LEU GLN GLY LEU ALA PHE SEQRES 10 A 298 CYS HIS SER HIS ARG VAL LEU HIS ARG ASP LEU LYS PRO SEQRES 11 A 298 GLN ASN LEU LEU ILE ASN THR GLU GLY ALA ILE LYS LEU SEQRES 12 A 298 ALA ASP PHE GLY LEU ALA ARG ALA PHE GLY VAL PRO VAL SEQRES 13 A 298 ARG THR TYR THR HIS GLU VAL VAL THR LEU TRP TYR ARG SEQRES 14 A 298 ALA PRO GLU ILE LEU LEU GLY CYS LYS TYR TYR SER THR SEQRES 15 A 298 ALA VAL ASP ILE TRP SER LEU GLY CYS ILE PHE ALA GLU SEQRES 16 A 298 MET VAL THR ARG ARG ALA LEU PHE PRO GLY ASP SER GLU SEQRES 17 A 298 ILE ASP GLN LEU PHE ARG ILE PHE ARG THR LEU GLY THR SEQRES 18 A 298 PRO ASP GLU VAL VAL TRP PRO GLY VAL THR SER MET PRO SEQRES 19 A 298 ASP TYR LYS PRO SER PHE PRO LYS TRP ALA ARG GLN ASP SEQRES 20 A 298 PHE SER LYS VAL VAL PRO PRO LEU ASP GLU ASP GLY ARG SEQRES 21 A 298 SER LEU LEU SER GLN MET LEU HIS TYR ASP PRO ASN LYS SEQRES 22 A 298 ARG ILE SER ALA LYS ALA ALA LEU ALA HIS PRO PHE PHE SEQRES 23 A 298 GLN ASP VAL THR LYS PRO VAL PRO HIS LEU ARG LEU SEQRES 1 B 261 VAL ASN GLU VAL PRO ASP TYR HIS GLU ASP ILE HIS THR SEQRES 2 B 261 TYR LEU ARG GLU MET GLU VAL LYS CYS LYS PRO LYS VAL SEQRES 3 B 261 GLY TYR MET LYS LYS GLN PRO ASP ILE THR ASN SER MET SEQRES 4 B 261 ARG ALA ILE LEU VAL ASP TRP LEU VAL GLU VAL GLY GLU SEQRES 5 B 261 GLU TYR LYS LEU GLN ASN GLU THR LEU HIS LEU ALA VAL SEQRES 6 B 261 ASN TYR ILE ASP ARG PHE LEU SER SER MET SER VAL LEU SEQRES 7 B 261 ARG GLY LYS LEU GLN LEU VAL GLY THR ALA ALA MET LEU SEQRES 8 B 261 LEU ALA SER LYS PHE GLU GLU ILE TYR PRO PRO GLU VAL SEQRES 9 B 261 ALA GLU PHE VAL TYR ILE THR ASP ASP THR TYR THR LYS SEQRES 10 B 261 LYS GLN VAL LEU ARG MET GLU HIS LEU VAL LEU LYS VAL SEQRES 11 B 261 LEU THR PHE ASP LEU ALA ALA PRO THR VAL ASN GLN PHE SEQRES 12 B 261 LEU THR GLN TYR PHE LEU HIS GLN GLN PRO ALA ASN CYS SEQRES 13 B 261 LYS VAL GLU SER LEU ALA MET PHE LEU GLY GLU LEU SER SEQRES 14 B 261 LEU ILE ASP ALA ASP PRO TYR LEU LYS TYR LEU PRO SER SEQRES 15 B 261 VAL ILE ALA GLY ALA ALA PHE HIS LEU ALA LEU TYR THR SEQRES 16 B 261 VAL THR GLY GLN SER TRP PRO GLU SER LEU ILE ARG LYS SEQRES 17 B 261 THR GLY TYR THR LEU GLU SER LEU LYS PRO CYS LEU MET SEQRES 18 B 261 ASP LEU HIS GLN THR TYR LEU LYS ALA PRO GLN HIS ALA SEQRES 19 B 261 GLN GLN SER ILE ARG GLU LYS TYR LYS ASN SER LYS TYR SEQRES 20 B 261 HIS GLY VAL SER LEU LEU ASN PRO PRO GLU THR LEU ASN SEQRES 21 B 261 LEU SEQRES 1 C 298 MET GLU ASN PHE GLN LYS VAL GLU LYS ILE GLY GLU GLY SEQRES 2 C 298 THR TYR GLY VAL VAL TYR LYS ALA ARG ASN LYS LEU THR SEQRES 3 C 298 GLY GLU VAL VAL ALA LEU LYS LYS ILE ARG LEU ASP THR SEQRES 4 C 298 GLU THR GLU GLY VAL PRO SER THR ALA ILE ARG GLU ILE SEQRES 5 C 298 SER LEU LEU LYS GLU LEU ASN HIS PRO ASN ILE VAL LYS SEQRES 6 C 298 LEU LEU ASP VAL ILE HIS THR GLU ASN LYS LEU TYR LEU SEQRES 7 C 298 VAL PHE GLU PHE LEU HIS GLN ASP LEU LYS LYS PHE MET SEQRES 8 C 298 ASP ALA SER ALA LEU THR GLY ILE PRO LEU PRO LEU ILE SEQRES 9 C 298 LYS SER TYR LEU PHE GLN LEU LEU GLN GLY LEU ALA PHE SEQRES 10 C 298 CYS HIS SER HIS ARG VAL LEU HIS ARG ASP LEU LYS PRO SEQRES 11 C 298 GLN ASN LEU LEU ILE ASN THR GLU GLY ALA ILE LYS LEU SEQRES 12 C 298 ALA ASP PHE GLY LEU ALA ARG ALA PHE GLY VAL PRO VAL SEQRES 13 C 298 ARG THR TYR THR HIS GLU VAL VAL THR LEU TRP TYR ARG SEQRES 14 C 298 ALA PRO GLU ILE LEU LEU GLY CYS LYS TYR TYR SER THR SEQRES 15 C 298 ALA VAL ASP ILE TRP SER LEU GLY CYS ILE PHE ALA GLU SEQRES 16 C 298 MET VAL THR ARG ARG ALA LEU PHE PRO GLY ASP SER GLU SEQRES 17 C 298 ILE ASP GLN LEU PHE ARG ILE PHE ARG THR LEU GLY THR SEQRES 18 C 298 PRO ASP GLU VAL VAL TRP PRO GLY VAL THR SER MET PRO SEQRES 19 C 298 ASP TYR LYS PRO SER PHE PRO LYS TRP ALA ARG GLN ASP SEQRES 20 C 298 PHE SER LYS VAL VAL PRO PRO LEU ASP GLU ASP GLY ARG SEQRES 21 C 298 SER LEU LEU SER GLN MET LEU HIS TYR ASP PRO ASN LYS SEQRES 22 C 298 ARG ILE SER ALA LYS ALA ALA LEU ALA HIS PRO PHE PHE SEQRES 23 C 298 GLN ASP VAL THR LYS PRO VAL PRO HIS LEU ARG LEU SEQRES 1 D 261 VAL ASN GLU VAL PRO ASP TYR HIS GLU ASP ILE HIS THR SEQRES 2 D 261 TYR LEU ARG GLU MET GLU VAL LYS CYS LYS PRO LYS VAL SEQRES 3 D 261 GLY TYR MET LYS LYS GLN PRO ASP ILE THR ASN SER MET SEQRES 4 D 261 ARG ALA ILE LEU VAL ASP TRP LEU VAL GLU VAL GLY GLU SEQRES 5 D 261 GLU TYR LYS LEU GLN ASN GLU THR LEU HIS LEU ALA VAL SEQRES 6 D 261 ASN TYR ILE ASP ARG PHE LEU SER SER MET SER VAL LEU SEQRES 7 D 261 ARG GLY LYS LEU GLN LEU VAL GLY THR ALA ALA MET LEU SEQRES 8 D 261 LEU ALA SER LYS PHE GLU GLU ILE TYR PRO PRO GLU VAL SEQRES 9 D 261 ALA GLU PHE VAL TYR ILE THR ASP ASP THR TYR THR LYS SEQRES 10 D 261 LYS GLN VAL LEU ARG MET GLU HIS LEU VAL LEU LYS VAL SEQRES 11 D 261 LEU THR PHE ASP LEU ALA ALA PRO THR VAL ASN GLN PHE SEQRES 12 D 261 LEU THR GLN TYR PHE LEU HIS GLN GLN PRO ALA ASN CYS SEQRES 13 D 261 LYS VAL GLU SER LEU ALA MET PHE LEU GLY GLU LEU SER SEQRES 14 D 261 LEU ILE ASP ALA ASP PRO TYR LEU LYS TYR LEU PRO SER SEQRES 15 D 261 VAL ILE ALA GLY ALA ALA PHE HIS LEU ALA LEU TYR THR SEQRES 16 D 261 VAL THR GLY GLN SER TRP PRO GLU SER LEU ILE ARG LYS SEQRES 17 D 261 THR GLY TYR THR LEU GLU SER LEU LYS PRO CYS LEU MET SEQRES 18 D 261 ASP LEU HIS GLN THR TYR LEU LYS ALA PRO GLN HIS ALA SEQRES 19 D 261 GLN GLN SER ILE ARG GLU LYS TYR LYS ASN SER LYS TYR SEQRES 20 D 261 HIS GLY VAL SER LEU LEU ASN PRO PRO GLU THR LEU ASN SEQRES 21 D 261 LEU SEQRES 1 E 5 ACE LEU ASN PFF NH2 MODRES 2WHA PFF E 4 PHE PHENYLALANINE-DERIVATIVE HET ACE E 1 3 HET PFF E 4 12 HET NH2 E 5 1 HETNAM ACE ACETYL GROUP HETNAM PFF 4-FLUORO-L-PHENYLALANINE HETNAM NH2 AMINO GROUP FORMUL 6 ACE C2 H4 O FORMUL 7 PFF C9 H10 F N O2 FORMUL 8 NH2 H2 N FORMUL 9 HOH *86(H2 O1) HELIX 1 1 PRO A 45 LYS A 56 1 12 HELIX 2 2 LEU A 87 SER A 94 1 8 HELIX 3 3 PRO A 100 SER A 120 1 21 HELIX 4 4 LYS A 129 GLN A 131 5 3 HELIX 5 5 ALA A 170 LEU A 175 1 6 HELIX 6 6 SER A 181 ARG A 199 1 19 HELIX 7 7 SER A 207 GLY A 220 1 14 HELIX 8 8 GLY A 229 MET A 233 5 5 HELIX 9 9 ASP A 247 VAL A 252 1 6 HELIX 10 10 ASP A 256 LEU A 267 1 12 HELIX 11 11 SER A 276 ALA A 282 1 7 HELIX 12 12 HIS A 283 GLN A 287 5 5 HELIX 13 13 TYR B 178 CYS B 193 1 16 HELIX 14 14 TYR B 199 GLN B 203 5 5 HELIX 15 15 THR B 207 TYR B 225 1 19 HELIX 16 16 GLN B 228 SER B 244 1 17 HELIX 17 17 LEU B 249 GLU B 269 1 21 HELIX 18 18 GLU B 274 ILE B 281 1 8 HELIX 19 19 THR B 287 THR B 303 1 17 HELIX 20 20 THR B 310 LEU B 320 1 11 HELIX 21 21 ASN B 326 ASP B 343 1 18 HELIX 22 22 ASP B 343 LEU B 348 1 6 HELIX 23 23 LEU B 351 GLY B 369 1 19 HELIX 24 24 PRO B 373 GLY B 381 1 9 HELIX 25 25 THR B 383 ALA B 401 1 19 HELIX 26 26 PRO B 402 HIS B 404 5 3 HELIX 27 27 GLN B 407 TYR B 413 1 7 HELIX 28 28 LYS B 414 HIS B 419 5 6 HELIX 29 29 GLY B 420 LEU B 424 5 5 HELIX 30 30 PRO C 45 LYS C 56 1 12 HELIX 31 31 LEU C 87 SER C 94 1 8 HELIX 32 32 PRO C 100 HIS C 121 1 22 HELIX 33 33 LYS C 129 GLN C 131 5 3 HELIX 34 34 ALA C 170 LEU C 175 1 6 HELIX 35 35 THR C 182 ARG C 199 1 18 HELIX 36 36 SER C 207 GLY C 220 1 14 HELIX 37 37 GLY C 229 MET C 233 5 5 HELIX 38 38 ASP C 247 VAL C 252 1 6 HELIX 39 39 ASP C 256 LEU C 267 1 12 HELIX 40 40 SER C 276 ALA C 282 1 7 HELIX 41 41 HIS C 283 GLN C 287 5 5 HELIX 42 42 TYR D 178 CYS D 193 1 16 HELIX 43 43 THR D 207 LYS D 226 1 20 HELIX 44 44 GLN D 228 MET D 246 1 19 HELIX 45 45 LEU D 249 GLU D 269 1 21 HELIX 46 46 GLU D 274 ILE D 281 1 8 HELIX 47 47 THR D 287 LEU D 302 1 16 HELIX 48 48 THR D 310 LEU D 320 1 11 HELIX 49 49 ASN D 326 ASP D 343 1 18 HELIX 50 50 ASP D 343 LEU D 348 1 6 HELIX 51 51 LEU D 351 THR D 368 1 18 HELIX 52 52 PRO D 373 GLY D 381 1 9 HELIX 53 53 LEU D 387 ALA D 401 1 15 HELIX 54 54 PRO D 402 HIS D 404 5 3 HELIX 55 55 GLN D 407 TYR D 413 1 7 HELIX 56 56 LYS D 414 HIS D 419 5 6 SHEET 1 AA 5 PHE A 4 GLU A 12 0 SHEET 2 AA 5 VAL A 17 ASN A 23 -1 O VAL A 18 N ILE A 10 SHEET 3 AA 5 VAL A 29 LYS A 34 -1 O VAL A 30 N ALA A 21 SHEET 4 AA 5 LEU A 76 GLU A 81 -1 O LEU A 78 N LYS A 33 SHEET 5 AA 5 LEU A 66 HIS A 71 -1 N LEU A 67 O VAL A 79 SHEET 1 AB 3 GLN A 85 ASP A 86 0 SHEET 2 AB 3 LEU A 133 ILE A 135 -1 O ILE A 135 N GLN A 85 SHEET 3 AB 3 ILE A 141 LEU A 143 -1 O LYS A 142 N LEU A 134 SHEET 1 AC 2 VAL A 123 LEU A 124 0 SHEET 2 AC 2 ARG A 150 ALA A 151 -1 O ARG A 150 N LEU A 124 SHEET 1 CA 5 PHE C 4 GLU C 12 0 SHEET 2 CA 5 VAL C 17 ASN C 23 -1 O VAL C 18 N ILE C 10 SHEET 3 CA 5 VAL C 29 ARG C 36 -1 O VAL C 30 N ALA C 21 SHEET 4 CA 5 LYS C 75 GLU C 81 -1 O LEU C 76 N ILE C 35 SHEET 5 CA 5 LEU C 66 HIS C 71 -1 N LEU C 67 O VAL C 79 SHEET 1 CB 3 GLN C 85 ASP C 86 0 SHEET 2 CB 3 LEU C 133 ILE C 135 -1 O ILE C 135 N GLN C 85 SHEET 3 CB 3 ILE C 141 LEU C 143 -1 O LYS C 142 N LEU C 134 SHEET 1 CC 2 VAL C 123 LEU C 124 0 SHEET 2 CC 2 ARG C 150 ALA C 151 -1 O ARG C 150 N LEU C 124 LINK C ACE E 1 N LEU E 2 1555 1555 1.32 LINK C ASN E 3 N PFF E 4 1555 1555 1.33 LINK C PFF E 4 N NH2 E 5 1555 1555 1.34 CISPEP 1 GLN B 323 PRO B 324 0 -13.35 CISPEP 2 ASP B 345 PRO B 346 0 17.07 CISPEP 3 GLN D 323 PRO D 324 0 -5.91 CRYST1 74.558 114.257 157.277 90.00 90.00 90.00 P 21 21 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.013412 0.000000 0.000000 0.00000 SCALE2 0.000000 0.008752 0.000000 0.00000 SCALE3 0.000000 0.000000 0.006358 0.00000